CN110577583A - Rgdf修饰的七环醛,其合成,抗栓活性和应用 - Google Patents
Rgdf修饰的七环醛,其合成,抗栓活性和应用 Download PDFInfo
- Publication number
- CN110577583A CN110577583A CN201810590224.0A CN201810590224A CN110577583A CN 110577583 A CN110577583 A CN 110577583A CN 201810590224 A CN201810590224 A CN 201810590224A CN 110577583 A CN110577583 A CN 110577583A
- Authority
- CN
- China
- Prior art keywords
- tetrahydro
- arg
- gly
- asp
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 3
- 238000003786 synthesis reaction Methods 0.000 title claims description 3
- 230000002785 anti-thrombosis Effects 0.000 title abstract description 7
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- ARNGIGOPGOEJCH-KKUMJFAQSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ARNGIGOPGOEJCH-KKUMJFAQSA-N 0.000 claims abstract description 4
- 108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- -1 2, 2-dimethoxyethyl-2-yl Chemical group 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 206010047249 Venous thrombosis Diseases 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 11
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 238000009833 condensation Methods 0.000 claims description 7
- 230000005494 condensation Effects 0.000 claims description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 2
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 238000006264 debenzylation reaction Methods 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 210000003462 vein Anatomy 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 12
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 229960002647 warfarin sodium Drugs 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000001631 vena cava inferior Anatomy 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- SOHLZANWVLCPHK-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-LBPRGKRZSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002796 renal vein Anatomy 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WSBJRDNLKQRURC-JHJMLUEUSA-N C1C(N[C@@H](C2=C1C3=CC=CC=C3N2)C=C=O)C(=O)O Chemical class C1C(N[C@@H](C2=C1C3=CC=CC=C3N2)C=C=O)C(=O)O WSBJRDNLKQRURC-JHJMLUEUSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了下式的Arg‑Gly‑Asp‑Phe修饰的七环醛,即(2’S,5’S)‑四氢吡嗪[1’,2’:1,6]并双{(1R)‑[1‑乙基‑Arg‑Gly‑Asp‑Phe]‑2,3,4,9‑四氢‑1H‑吡啶[3,4‑b]并吲哚}‑1’,4’‑二酮,公开了它的制备方法,公开了它的抗静脉血栓活性,抗静脉血栓剂量依赖关系,因而本发明公开了它在制备抗静脉血栓药物中的应用。。
Description
技术领域
本发明涉及(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮,涉及它的制备方法,涉及它的抗静脉血栓活性,抗静脉血栓剂量依赖关系,因而本发明涉及它在制备抗静脉血栓药物中的应用。本发明属于生物医药领域。
背景技术
动脉血栓和静脉血栓两种病症已成为当下发病率高和死亡率高的疾病,在全球范围内,缺血性心脏病和缺血性中风导致的死亡人数占全部因病死亡人数的1/4。而静脉血栓则是不发达国家,中等发达国家和高度发达国家主要的疾病负担。静脉血栓症主要包括深静脉血栓和肺栓塞。深静脉血栓和肺栓塞发病的患者数超过了心肌梗塞和中风发病的总人数,而且比乳腺癌和艾滋病所引起死亡的总人数高。由于静脉血栓症的发病率随年龄增长呈指数态增加,所以这种病症对我国这样的老龄化国家的人民健康的威胁尤其严重。如果把人口基数考虑进去,对我国国计民生的绝对负面影响尤其严重。于是,静脉血栓症的预防及治疗一直是医药领域所关注的重点,发明新型抗静脉血栓药物具有临床重要性。
β-咔啉是抑制血栓的重要药效团。发明人假设,两个β-咔啉药效团融合,例如两个(R)-1-羰甲基-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚-3-羧酸分子间缩合为(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮。这种新型七环醛,应有强的抗静脉血栓活性。发明人进一步假设,往这种新型七环醛的醛基连接Arg-Gly-Asp-Phe应有更强的抗静脉血栓活性。根据这个假设,发明人提出了本发明。
发明内容
本发明的第一个内容是提供下式的(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮。
本发明的第二个内容是提供(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮的制备方法,该方法包括:
1)将L-色氨酸苄酯在三氟醋酸的催化下与1,1,3,3-四甲氧基丙烷进行Pictet-Spengler缩合,得到(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯(1);
2)在甲醇中(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯在Pd/C催化下氢解脱苄得到(3S)-1-(2,2-二甲氧乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸(2);
3)在苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸酯(HBTu)存在下,(3S)-1-(2,2-二甲氧乙基-2基)-2,3,4,9-四氢-β-咔啉-3-羧酸在无水DMF(N,N-二甲基甲酰胺)中分子间缩合为(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(3);
4)采用冰醋酸为溶剂,浓盐酸和水为催化剂(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(3)转化为(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(4);
5)采用二环己基碳二亚胺为缩合剂,1-羟基苯并三唑为催化剂的液相缩合的方法合成HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl;
6)用氰基硼氢化钠为还原剂将HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl连接到(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(4)的醛基上,合成(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(5);
7)在三氟醋酸和三氟甲磺酸的混合溶剂中(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(5)脱除硝基和苄酯得到(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(6)。
本发明的第三个内容是评价(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮的抗静脉血栓作用。
附图说明
图1.(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮的合成路线.(i)二氯甲烷,三氟醋酸;(ii)CH3OH,Pd/C,H2;(iii)HBTu,NMM,无水DMF;(iv)H2O,冰醋酸,浓盐酸;(v)DCC,HOBt,NMM,THF;(vi)氯化氢的乙酸乙酯溶液(4M);(vii)CH3OH,NaOH溶液(2M);(viii)二氯甲烷,NaCNBH3,无水MgSO4;(ix)三氟醋酸,三氟甲磺酸。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯(1)
冰浴下180mL二氯甲烷,10mL 1,1,3,3-四甲氧基丙烷和10mL三氟醋酸的混合溶液搅拌40min。之后,后加入10.25g(34.86mmol)L-Trp-OBzl。反应混合物室温搅拌14h,TLC(石油醚/乙酸乙酯=1:1)显示L-Trp-OBzl消失。反应液分别用饱和NaHCO3水溶液洗(40mL×3),饱和NaCl水溶液洗(40mL×3),分离的二氯甲烷用无水硫酸钠干燥12h,过滤,滤液减压浓缩,残留物用硅胶柱层析进行纯化(石油醚/乙酸乙酯=3:1),得5.12g(37%)标题化合物,为棕红色油状物。ESI-MS(m/e):393[M+H]-。
实施例2制备(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸(2)
向5.12g(13.00mmol)(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯与100mL甲醇的溶液中加入500mg Pd/C,充入氢气并室温搅拌18h,TLC(石油醚/乙酸乙酯=1:1)显示1消失,终止反应。滤除Pd/C,滤液减压浓缩至干,得3.63g(92%)标题化合物,为亮黄色油状物。ESI-MS(m/e):303[M-H]-。
实施例3制备(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(3)
冰浴搅拌下向6.12g(20.13mmol)(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸(2)与100mL无水DMF的溶液中加入3.00g(22.22mmol)HBTu。然后用N-甲基吗啉将反应液的pH调至8-9,反应24h后点TLC(石油醚/乙酸乙酯=1:1)显示2消失,终止反应。反应液减压浓缩,残留物用150mL乙酸乙酯溶解。之后,分别用饱和N aHCO3水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),5%KHSO4水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),饱和NaHCO3水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3)。乙酸乙酯层用无水硫酸钠干燥12h,过滤,滤液减压浓缩。得到的深黄色固体用硅胶柱层析分离(石油醚/乙酸乙酯=2:1),得1.14g(10%)标题化合物,为黄色固体。ESI-MS(m/e):573[M+H]+;1HNMR(300MHz,DMSO-d6)δ/ppm=11.08(s,2H),7.39(d,J=7.5Hz,2H),7.34(d,J=8.1Hz,2H),7.08(t,J=7.2Hz,2H),6.97(t,J=7.2Hz,2H),5.93(dd,J1=3.6Hz,J2=9.0Hz,2H),4.62(dd,J1=3.3Hz,J2=11.4Hz,2H),4.53(t,J=4.8Hz,2H),3.34(s,6H),3.26(s,6H),3.20(m,2H),2.79(m,2H),2.24(m,4H)。
实施例4制备(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(4)
冰浴与搅拌下向380mg(0.66mmol)(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(3)和9mL冰醋酸的溶液中加入6mL水和3mL浓盐酸,搅拌2h,TLC显示(石油醚/乙酸乙酯=1:1)3消失,终止反应。冰浴下,用NaOH水溶液(2M)调节反应液pH值到7。得到的溶液用乙酸乙酯萃取(50mL×3),合并的乙酸乙酯层分别用饱和NaHCO3水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),乙酸乙酯相用无水硫酸钠进行干燥12h,滤去硫酸钠,滤液减压浓缩得到288mg(90%)标题化合物,为黄色固体。ESI-MS(m/e):481[M+H]+;1H-NMR(300MHz,DMSO-d6)δ/ppm=10.95(s,2H),9.79(m,2H),7.42(d,J=8.1Hz,2H),7.38(d,J=7.5Hz,2H),7.10(t,J=6.9Hz,2H),6.99(t,J=6.9Hz,2H),6.22(dd,J1=3.6Hz,J2=9.0Hz,2H),4.67(dd,J1=3.3Hz,J2=11.4Hz,2H),3.26(m,2H),3.11(m,4H),2.84(m,2H)。
实施例5制备Boc-Arg(NO2)-Gly-OBzl
冰浴下向3.19g(10.00mmol)Boc-Arg(NO2)与150mL无水四氢呋喃的溶液中加入1.35g(10.00mmol)HOBt,搅拌5min后加入2.27g(11.00mmol)DCC,冰浴下搅拌30min,得到反应液A。冰浴下,将3.50g(12.00mmol)HCl·Gly-OBzl加入反应液A中,用N-甲基吗啉调节pH值到9。反应混合物室温搅拌反20h,TLC(二氯甲烷/甲醇=20:1)显示Boc-Arg(NO2)消失。滤除反应液中的不溶物,滤液减压浓缩,残留物用150mL乙酸乙酯溶解,滤去不溶的无色固体,滤液分别用饱和NaHCO3水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),5%KHSO4水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),饱和NaHCO3水溶液洗(30mL×3),饱和NaCl水溶液洗(30mL×3),得到的乙酸乙酯相用无水硫酸钠干燥12h,滤去硫酸钠,滤液减压浓缩,得到黄色糖浆,加入30mL二氯甲烷溶解,置于4℃静置12h;析出白色固体,减压过滤,得到4.32g(93%)标题化合物,为无色固体。ESI-MS(m/e):467[M+H]+。
实施例6制备Boc-Arg(NO2)-Gly
冰浴下向4.32g(9.25mmol)Boc-Arg(NO2)-Gly-OBzl与30mL甲醇的溶液中滴加2MNaOH溶液,调节溶液pH值为13-14。反应混合物冰浴搅拌反1h,TLC(二氯甲烷/甲醇/乙酸,20/1/2滴,v/v/v)显示Boc-Arg(NO2)-Gly-OBzl消失。于冰浴下滴加饱和KHSO4溶液,调节溶液的pH为7,减压旋除甲醇。残留物于冰浴下滴加饱和KHSO4溶液,调节溶液的pH为2-3,用乙酸乙酯萃取(50mL×3),合并乙酸乙酯层,用饱和NaCl水溶液洗(30mL×3),得到的乙酸乙酯相用无水硫酸钠干燥12h,滤去硫酸钠,滤液减压浓缩,3.21g(92%)标题化合物,为无色糖浆。
实施例7制备Boc-Asp(OBzl)-Phe-OBzl
按照实施例5的方法从3.23g(10.00mmol)Boc-Asp(OBzl)和3.50g(12.00mmol)HCl·Phe-OBzl得到5.14g(92%)标题化合物,为黄色糖浆。ESI-MS(m/e):561[M+H]+。
实施例8制备HCl·Asp(OBzl)-Phe-OBzl
将5.14g(9.18mmol)Boc-Asp(OBzl)-Phe-OBzl用20mL无水乙酸乙酯溶解,然后于冰浴下向溶液中加入50mL氯化氢的乙酸乙酯溶液(4M),室温搅拌6h,TLC(二氯甲烷/甲醇/乙酸,30/1/2滴,v/v/v)显示Boc-Asp(OBzl)-Phe-OBzl消失。将反应液减压浓缩,残留物用无水乙酸乙酯复溶后再减压浓缩,再用无水乙酸乙酯复溶。该操作至少重复3次。最后残留物用无水乙醚洗,得到4.25g(93%)标题化合物,为黄色固体。
实施例9制备Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl
按照实施例5的方法从2.50g(6.65mmol)Boc-Arg(NO2)-Gly和3.96g(7.98mmol)HCl·Asp(OBzl)-Phe-OBzl得到3.29g(61%)标题化合物,为无色粉末。ESI-MS(m/e):819[M+H]+。
实施例10制备HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl
按照实施例8的方法从1.18g(1.44mmol)Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得到1.04g(96%)标题化合物,为无色固体。
实施例11(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(5)
将220mg(0.46mmol)(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(4)溶于15mL二氯甲烷,冰浴下以三乙胺调节pH值到9。将1.04g(1.38mmol)HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl用15mL二氯甲烷溶解,冰浴下以三乙胺调节pH值到9,于冰浴下滴加到化合物4的二氯甲烷溶液中,加100mg MgSO4。反应混合物冰浴搅拌1h后,每隔1h加入36mg NaCNBH3,共加入144mg NaCNBH3。之后,在室温搅拌24hTLC(二氯甲烷/甲醇=7:1)显示化合物4消失,终止反应。反应液分别用饱和NaHCO3水溶液洗(7mL×3),饱和NaCl水溶液洗(7mL×3),得到的二氯甲烷相用无水硫酸钠干燥12h后,滤去硫酸钠,滤液减压浓缩,得到的黄色固体用硅胶柱层析纯化(二氯甲烷/甲醇=20:1),得到156mg(18%)标题化合物,为淡黄色固体。ESI-MS(m/e):1886[M+H]+;1H-NMR(300MHz,DMSO-d6)δ/ppm=10.99(s,2H),8.60(m,2H),8.47(d,J=7.5Hz,2H),8.37(d,J=8.1Hz,2H),8.26(m,2H),7.39~7.15(m,34H),7.07(t,J=7.8Hz,2H),6.96(t,J=7.5Hz,2H),5.94(m,2H),5.04(m,8H),4.76(dd,J1=8.1Hz,J2=13.5Hz,2H),4.57(dd,J1=3.3Hz,J2=11.1Hz,2H),4.49(dd,J1=7.8Hz,J2=15.0Hz,2H),3.80(m,4H),3.25(m,2H),3.17(m,8H),3.01(m,6H),2.81~2.55(m,10H),2.27(m,2H),2.07(m,4H),1.63(m,8H)。
实施例12制备(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(6)
冰浴下将100mg(0.05mmol)(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(5)用3mL三氟乙酸溶解。之后,加入1mL三氟甲磺酸,冰浴下搅拌30min,TLC(二氯甲烷/甲醇=7:1)显示化合物5消失。冰浴下往反应混合物中加50mL无水乙醚,搅拌10min,静置,倾去上清液。残留物再加50mL无水乙醚,搅拌10min,静置,倾去上清液。该操作至少重复3次。得到的黄黑色固体用1.5mL 5%醋酸溶解,溶液用Sephadex纯化,得到31mg(41%)标题化合物,为淡黄色固体。ESI-MS(m/e):1435[M+H]+;1H-NMR(300MHz,DMSO-d6)δ/ppm=12.68(s,4H),10.75(s,2H),9.17(m,2H),8.92(m,2H),8.47(d,J=7.5Hz,2H),8.25(m,2H),7.42(m,8H),7.19(m,10H),7.14(m,2H),7.01(t,J=7.2Hz,2H),5.77(m,2H),4.68(dd,J1=8.7Hz,J2=12.9Hz,2H),4.56(dd,J1=3.6Hz,J2=10.8Hz,2H),4.40(dd,J1=8.1Hz,J2=13.5Hz,2H),3.94(m,4H),3.25(m,2H),3.14(m,8H),3.01(m,6H),2.91~2.68(m,8H),2.49(m,2H),2.38(m,2H),2.28(m,2H),1.78(m,4H),1.55(m,4H)。
实施例13评价(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(6)的抗静脉血栓作用
实验材料:华法林钠(CAS:129-06-6,百灵威科技有限公司)、乌拉坦(CAS:51-79-6,货号:30191228,国药集团化学试剂有限公司)、生理盐水(石家庄四药有限公司)、二水合柠檬酸三钠(CMCNa,货号:20170713,北京化工厂)。
实验动物:SD品系大鼠,雄性,250±20g,购自北京维通利华实验动物技术有限公司。
实验方法:实验采用大鼠下腔静脉结扎模型。
分组及剂量:(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(简称化合物6)的剂量为0.1μmol/kg,阳性对照华法林钠的剂量为4.87μmol/kg,阴性对照为0.5%CMCNa。
试剂的剂型:麻醉剂为乌拉坦的生理盐水溶液(20%),化合物6为0.5%CMCNa的悬浮液,华法林钠为0.5%CMCNa的悬浮液。
实验操作:大鼠在手术前适应环境并禁食一天,以0.3mL/100g体重的剂量对大鼠进行灌胃给药。给药30min后于手术前2min用20%乌拉坦溶液腹腔给药麻醉。将大鼠固定于大鼠固定板上,腹部备皮且消毒,然后沿腹白线打开腹腔,上至露出肝脏一角,开口大小约4cm长即可。移开腹腔内小肠等器官并用浸润过生理盐水的纱布包裹。钝性分离血管周围结缔组织,暴露下腔静脉及其分支,在左肾静脉下方将腹主动脉和下腔静脉剥离开,然后用生理盐水浸湿的缝合线在下腔静脉与左肾静脉交汇处将下腔静脉结扎,按解剖位置将肠等器官移回腹腔,用缝合线逐层缝合腹腔。
术后将大鼠置于25~28℃的环境中循环4小时,打开腹腔后,逐个将其分支结扎,从下腔静脉与左肾静脉的交汇处的结扎处开始取出2cm下腔静脉,从中取出血栓。血栓称重并利用t检验的方式统计结果。手术以每组四只交替进行。实验数据见表1。
表1的数据表明,在0.1μmol/kg口服剂量下化合物6不仅可显著性抑制大鼠形成静脉血栓,而且活性明显强于4.87μmol/kg华法林钠。本发明有意想不到的技术效果。
表1化合物6的抗静脉血栓活性
化合物 | 剂量 | 血栓重(均值±SD mg) |
0.5%CMCNa | 3mL/kg | 21.74±4.51 |
华法林钠 | 4.87μmol/kg | 14.52±5.17 |
化合物6 | 0.1μmol/kg | 9.22±3.13<sup>a</sup> |
a)与0.5%CMCNa比P<0.01,与4.87μmol/kg华法林钠比P<0.05;n=8
实施例14评价(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮(6)的抗静脉血栓的剂量依赖关系
实验材料:华法林钠(CAS:129-06-6,百灵威科技有限公司)、乌拉坦(CAS:51-79-6,货号:30191228,国药集团化学试剂有限公司)、生理盐水(石家庄四药有限公司)、二水合柠檬酸三钠(CMCNa,货号:20170713,北京化工厂)。
实验动物:SD品系大鼠,雄性,250±20g,购自北京维通利华实验动物技术有限公司。
实验方法:实验采用大鼠下腔静脉结扎模型。
分组及剂量:化合物6的剂量分别为0.1μmol/kg,0.01μmol/kg,0.001μmol/kg,阳性对照华法林钠的剂量为4.87μmol/kg,阴性对照为0.5%CMCNa。
试剂的剂型:麻醉剂为乌拉坦的生理盐水溶液(20%),化合物6为0.5%CMCNa的悬浮液,华法林钠为0.5%CMCNa的悬浮液。
实验操作:同实施例13,实验数据见表2。
表2的数据表明,化合物6剂量(0.1μmol/kg、0.01μmol/kg和0.001μmol/kg)依赖地抑制静脉血栓形成,最低有效剂量为0.01μmol/kg。本发明有意想不到的技术效果。
表2化合物6的抗静脉血栓活性
a)与0.5%CMCNa及0.01μmol/kg化合物6比P<0.01,与4.87μmol/kg华法林钠比P<0.05;
b)与0.5%CMCNa及0.001μmol/kg化合物6比P<0.01;c)与0.5%CMCNa比P>0.05;n=8。
Claims (3)
1.下式的Arg-Gly-Asp-Phe修饰七环醛,即(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮,
2.权利要求1的Arg-Gly-Asp-Phe修饰七环醛的制备方法,该方法包括:
1)将L-色氨酸苄酯在三氟醋酸的催化下与1,1,3,3-四甲氧基丙烷进行Pictet-Spengler缩合,得到(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯;
2)在甲醇中(3S)-1-(2,2-二甲氧基乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸苄酯在Pd/C催化下氢解脱苄得到(3S)-1-(2,2-二甲氧乙基-2-基)-2,3,4,9-四氢-β-咔啉-3-羧酸;
3)在苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸酯存在下,(3S)-1-(2,2-二甲氧乙基-2基)-2,3,4,9-四氢-β-咔啉-3-羧酸在无水DMF中分子间缩合为(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮;
4)采用冰醋酸为溶剂,浓盐酸和水为催化剂(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-二甲氧乙基-2-基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮转化为(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮;
5)采用二环己基碳二亚胺为缩合剂,1-羟基苯并三唑为催化剂的液相缩合的方法合成HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl;
6)用氰基硼氢化钠为还原剂将HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl连接到(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-羰甲基]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮的醛基上,合成(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮;
7)在三氟醋酸和三氟甲磺酸的混合溶剂中(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮脱除硝基和苄酯得到(2’S,5’S)-四氢吡嗪[1’,2’:1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Phe]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1’,4’-二酮。
3.权利要求1的Arg-Gly-Asp-Phe修饰七环醛在制备抗静脉血栓药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810590224.0A CN110577583B (zh) | 2018-06-08 | 2018-06-08 | Rgdf修饰的七环醛,其合成,抗栓活性和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810590224.0A CN110577583B (zh) | 2018-06-08 | 2018-06-08 | Rgdf修饰的七环醛,其合成,抗栓活性和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110577583A true CN110577583A (zh) | 2019-12-17 |
CN110577583B CN110577583B (zh) | 2021-07-02 |
Family
ID=68809135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810590224.0A Expired - Fee Related CN110577583B (zh) | 2018-06-08 | 2018-06-08 | Rgdf修饰的七环醛,其合成,抗栓活性和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110577583B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754723A (zh) * | 2020-06-04 | 2021-12-07 | 首都医科大学 | Rgdf修饰的姜黄素的合成,生物活性和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190940A (zh) * | 2006-11-30 | 2008-06-04 | 首都医科大学 | 具有靶向抗血栓活性的多肽、其制备方法和应用 |
CN103450334A (zh) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Rgd肽修饰的咔啉并六氢吡嗪-1,4-二酮、其制备方法、抗血栓作用和应用 |
CN107488212A (zh) * | 2016-06-13 | 2017-12-19 | 首都医科大学 | 华法林‑4‑o‑乙酰‑rgd四肽, 其合成, 活性和应用 |
CN109912694A (zh) * | 2017-12-12 | 2019-06-21 | 首都医科大学 | Rgdf修饰的七环醛, 其制备,抗栓活性和应用 |
-
2018
- 2018-06-08 CN CN201810590224.0A patent/CN110577583B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190940A (zh) * | 2006-11-30 | 2008-06-04 | 首都医科大学 | 具有靶向抗血栓活性的多肽、其制备方法和应用 |
CN103450334A (zh) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Rgd肽修饰的咔啉并六氢吡嗪-1,4-二酮、其制备方法、抗血栓作用和应用 |
CN107488212A (zh) * | 2016-06-13 | 2017-12-19 | 首都医科大学 | 华法林‑4‑o‑乙酰‑rgd四肽, 其合成, 活性和应用 |
CN109912694A (zh) * | 2017-12-12 | 2019-06-21 | 首都医科大学 | Rgdf修饰的七环醛, 其制备,抗栓活性和应用 |
Non-Patent Citations (4)
Title |
---|
HAIMEI ZHU等: "Design, synthesis and evaluation of a novel π-π stacking nano-intercalator as an anti-tumor agent", 《MEDCHEMCOMM》 * |
HAIMEI ZHU等: "Docking of THPDTPI:to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent", 《ONCOTARGET》 * |
刘南等主编: "《血液系统疾病综合诊疗要点 上》", 30 April 2016, 吉林科学技术出版社 * |
李家增,贺石林,王鸿利主编: "《临床血栓病学》", 31 October 2014, 上海交通大学出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754723A (zh) * | 2020-06-04 | 2021-12-07 | 首都医科大学 | Rgdf修饰的姜黄素的合成,生物活性和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110577583B (zh) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107686483B (zh) | 七环缩醛,其制备,抗栓活性和应用 | |
CN109912597B (zh) | 七环醛,其合成,抗栓活性和应用 | |
CN110577530B (zh) | 七环醛,其合成,抗栓活性和应用 | |
CN109912693B (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
CN110577583B (zh) | Rgdf修饰的七环醛,其合成,抗栓活性和应用 | |
CN110563799B (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
CN109912694B (zh) | Rgdf修饰的七环醛,其合成,抗栓活性和应用 | |
CN109912692B (zh) | Yigsk修饰的七环醛,其制备,抗栓活性和应用 | |
CN110551126B (zh) | 氨基酸修饰的s,r-七环醛,其合成,活性及应用 | |
CN110577569B (zh) | Rgdv修饰的七环醛,其合成,抗栓活性和应用 | |
CN110577571B (zh) | Yigsk修饰的七环醛,其合成,抗栓活性和应用 | |
CN110577582B (zh) | Ldv修饰的七环醛,其合成,抗栓活性和应用 | |
CN108976285B (zh) | Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用 | |
CN109912695B (zh) | Rgdv修饰的七环醛,其合成,抗栓活性和应用 | |
WO2018068696A1 (zh) | 一种青藤碱及其衍生物的peg修饰物、其制备方法和用途 | |
CN110551127B (zh) | 氨基酸修饰的ss-七环醛,其制备,活性和应用 | |
CN105585612A (zh) | 八肽修饰的地塞米松、制备、纳米结构和应用 | |
CN111995661B (zh) | 乙基arpak修饰的双咔啉并哌嗪二酮,其制备,活性和应用 | |
CN101265292B (zh) | 多肽类物质、其制备方法及其用途 | |
CN112010937B (zh) | Yigsr修饰的五环哌嗪二酮及其制备和应用 | |
CN108948139B (zh) | 华法林-4-O-乙酰-Arg-AA化合物,其合成,活性和应用 | |
CN108948140B (zh) | 华法林-4-O-乙酰-Arg-AA十一种化合物,其合成,活性和应用 | |
CN110577570A (zh) | Rgd四肽修饰的s,r-七环醛,其合成,活性和应用 | |
CN113754725B (zh) | 二甲基二氧六环-四氢-β-咔啉-3-甲酰-RGDV的合成,生物活性和应用 | |
CN112010930B (zh) | Rgd修饰的五环哌嗪二酮及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210702 |